GlassScriptPhysician profile
Abraham Goodgold
NPI 1184791980
$6,100.72
in general payments reported to CMS, 2019-2025
35 companies · $747 in 2025
The $747 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $1,180 · 2021: $659 · 2022: $923 · 2023: $936 · 2024: $749 · 2025: $747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $851.04 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $821.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $492.68 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Sanofi-Aventis U.S. LLC | $441.90 | 2019-2025 | |
| Abbvie INC. | $438.87 | 2021-2025 | |
| Dexcom, INC. | $372.86 | 2021-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $261.45 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $210.02 | 2019-2025 | |
| Pfizer INC. | $208.22 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $190.86 | 2019-2021 | |
| Abbott Laboratories | $171.75 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.05 | 2023-2025 | Xifaxan, Trulance |
| Merck Sharp & Dohme LLC | $156.55 | 2019-2023 | Verquvo, Steglatro, Belsomra |
| Allergan, INC. | $129.04 | 2019-2020 | |
| Amarin Pharma, INC. | $128.86 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $124.64 | 2019-2025 | Arexvy, Shingrix, Bexsero |
| Qiagen, LLC | $119.78 | 2020 | |
| Corcept Therapeutics | $104.65 | 2025 | Korlym |
| Mannkind Corporation | $103.93 | 2019-2020 | |
| Senseonics, Incorporated | $92.00 | 2019 | |
| Astellas Pharma US INC | $71.62 | 2019-2024 | Veozah |
| Exact Sciences Corporation | $60.07 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $56.53 | 2022-2023 | Ztlido |
| Arbor Pharmaceuticals, INC. | $45.72 | 2020-2021 | |
| Genentech USA, INC. | $44.29 | 2020-2021 | |
| Lundbeck LLC | $35.38 | 2023-2025 | Rexulti |
| Neurocrine Biosciences, INC. | $34.00 | 2023 | Ingrezza |
| Xeris Pharmaceuticals, INC. | $31.38 | 2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $29.89 | 2020 | |
| Amgen INC. | $25.40 | 2019-2022 | |
| Depuy Synthes Sales INC. | $23.29 | 2024 | Orthovisc |
| Teva Pharmaceuticals USA, INC. | $16.89 | 2023 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $16.73 | 2024 | Rexulti |
| Daiichi Sankyo INC. | $14.99 | 2021 | |
| Metuchen Pharmaceuticals | $11.74 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abraham Goodgold listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.